ASCO 2021: The Voice of China!

2021 On 6 Yue 7 May 2021 annual ASCO (American Society of Clinical Oncology) Annual Meeting at the plenary session " heavy Abstract " ( LBA , Late-Breaking the Abstract ) form, the king issued a real biological self-developed anti- PD- 1 The latest results of the first-line treatment of relapsed / metastatic nasopharyngeal carcinoma ( Jupiter-02 study) with the monoclonal antibody drug teriprolizumab combined with chemotherapy .

2021 On 6 Yue 7 May 2021 annual ASCO ASCO (American Society of Clinical Oncology) Annual Meeting at the plenary session " heavy Abstract " ( LBA , Late-Breaking the Abstract ) form, the king issued a real biological self-developed anti- PD -1 The latest results of the first-line treatment of relapsed / metastatic nasopharyngeal carcinoma ( Jupiter-02 study) with the monoclonal antibody drug teriprolizumab combined with chemotherapy .

Nasopharyngeal carcinoma is a malignant tumor that occurs in the mucosal epithelium of the nasopharyngeal area and is one of the common malignant tumors of the head and neck.

Nasopharyngeal carcinoma is a malignant tumor that occurs in the mucosal epithelium of the nasopharyngeal area and is one of the common malignant tumors of the head and neck.

At present, treatment options are limited.

Professor Ruihua Xu introduced the JUPITER-02 research at the plenary session of the ASCO annual meeting

Professor Xu Ruihua at ASCO introduced the annual plenary session JUPITER-02 Research Professor Xu Ruihua at ASCO ASCO introduced the annual plenary session JUPITER-02 JUPITER-02 study

The selected JUPITER-02 study ( NCT03581786 ) is a randomized, double-blind, placebo-controlled, global multi-center Phase III trial.

The selected JUPITER-02 study ( NCT03581786 ) is a randomized, double-blind, placebo-controlled, global multi-center Phase III trial.

The study in mainland China, China Taiwan, Singapore enrolled since 2018 Nian 11 Yue Zhi 2019 Nian 10 Yue 2018 11 2019 10 289 patients did not received chemotherapy for recurrent / metastatic nasopharyngeal carcinoma were randomized ( 1 : 1 ) patient allocation To teriprizumab ( 240mg, Q3W ) combined with chemotherapy (gemcitabine and cisplatin, GP ) group (teriprolizumab group, n=146 ) or placebo combined with chemotherapy group (placebo group, n=143 ) Receive treatment, and continue to receive teriprizumab ( Q3W ) or placebo as a single-agent maintenance treatment after 6 cycles , until the completion of 2 years of treatment, or until the disease progresses, or intolerable toxicity occurs.

As of 2020 Nian 5 Yue 30 Ri interim analysis showed 2020 5 30 , with a median Terry Plymouth monoclonal antibody treatment duration group median Terry Plymouth group of monoclonal antibody treatment duration was 39 weeks, the placebo group was 36 week.

As of 2021 Nian 2 Yue 18 Ri, JUPITER-02 study of OS is not yet mature, but it has been observed Terry Plymouth monoclonal antibody combination treatment group benefited trends in overall survival, which reduces the risk of death by 40% .

The results of the study showed that compared with chemotherapy alone, the combination of teriprizumab and chemotherapy alone, the combination of teriprizumab and chemotherapy alone, and the combination of teriprizumab and GP chemotherapy for the first-line treatment of relapse / Metastatic nasopharyngeal carcinoma can obtain better PFS , higher ORR and longer DOR , and has good safety and tolerability.

" Compared with some other types of cancer, the treatment of advanced nasopharyngeal carcinoma has fallen behind, but the results of the JUPITER-02 study have brought new hopes for patients to improve the efficacy, and will also change our treatment of nasopharyngeal carcinoma.

" Nasopharyngeal carcinoma is a highly aggressive malignant tumor, especially for patients with recurrent / metastatic nasopharyngeal carcinoma.

In the field of nasopharyngeal cancer treatment, Junshi Bio has deployed a " full-line " clinical study of teriprizumab single-drug or combination therapy on a global scale .

In addition, the current monarch in real biological ASCO recent annual meeting of the 40 Xiang was selected summary, there are as many as many as many as 10 Xiang Terry Plymouth mAb auxiliary / neoadjuvant / 10 10 Xiang Terry Plymouth mAb Auxiliary items: Tripriximab Adjuvant / / Neoadjuvant Neoadjuvant / / Perioperative treatment of non-small cell lung cancer, esophageal cancer, gastric cancer , mucosal melanoma, etc.

At the same time, there are also a number of latest research data on the treatment of liver cancer and intrahepatic cholangiocarcinoma ( liver cancer, intrahepatic cholangiocarcinoma liver cancer, intrahepatic cholangiocarcinoma ICC ) with teriprizumab at the ASCO annual meeting.

" In view of its outstanding research results, the JUPITER-02 study is the first global multicenter study that has made significant progress in the first-line treatment of advanced nasopharyngeal cancer since gemcitabine and cisplatin chemotherapy were identified as standard treatments.
Given its outstanding As a result of the study, the JUPITER-02 study is the first global multicenter study that has made significant progress in the first-line treatment of advanced nasopharyngeal cancer since gemcitabine and cisplatin chemotherapy were identified as standard treatments.
In view of its outstanding research results, JUPITER- 02 The study is the first global multi-center study that has made significant progress in the first-line treatment of advanced nasopharyngeal cancer since gemcitabine and cisplatin chemotherapy were identified as standard treatments.
We will accelerate the availability of teriprizumab in China, the United States and the United States.
Commercialization in other countries in order to bring this exciting new treatment option to more nasopharyngeal cancer patients, " said Dr.
Patricia Keegan , Chief Medical Officer of Junshi Bio .
" In addition to the JUPITER-02 trial, during the ASCO annual meeting, we will also announce the results of a number of studies in other areas of teriplizumab to provide support for our current development strategy.
We have targeted a variety of high-incidence solid tumors in China, For example, esophageal cancer, gastric cancer, liver cancer and non-small cell lung cancer, as well as the relatively high incidence of mucosal subtypes of melanoma in Asia, have carried out adjuvant / neoadjuvant immunotherapy research.
In addition, we are also exploring the use of teriprizumab in the liver There is no checkpoint inhibitor approved for the treatment of internal cholangiocarcinoma in this field.
"

references:

references:

1. https://gco.
   iarc.
   fr/today/data/factsheets/cancers/4-Nasopharynx-fact-sheet.
   pdf.
   
2. https://gco.
   iarc.
   fr/today/data/factsheets/populations/160-china-fact-sheets.
   pdf.
   
3. Chen YP, et al.
   Lancet 2019.
   394:64-80,
4. Nasopharyngeal Cancer Professional Committee of Chinese Anti-Cancer Association .
   Chinese Journal of Radiation Oncology.
   2018;27(1):7-15.
   
5. https://ascopubs.
   org/doi/abs/10.
   1200/JCO.
   2020.
   38.
   15_suppl.
   6521.
   

https://gco.
iarc.
fr/today/data/factsheets/cancers/4-Nasopharynx-fact-sheet.
pdf.

https://gco.
iarc.
fr/today/data/factsheets/cancers/4-Nasopharynx-fact-sheet.
pdf.

https://gco.
iarc.
fr/today/data/factsheets/populations/160-china-fact-sheets.
pdf.

https://gco.
iarc.
fr/today/data/factsheets/populations/160-china-fact-sheets.
pdf.

Chen YP, et al.
Lancet 2019.
394:64-80,

Chen YP, et al.
Lancet 2019.
394:64-80,

Nasopharyngeal Cancer Professional Committee of Chinese Anti-Cancer Association .
Chinese Journal of Radiation Oncology.
2018;27(1):7-15.

Nasopharyngeal Cancer Professional Committee of the Chinese Anti-Cancer Association .
Chinese Journal of Radiation Oncology.
2018; 27(1): 7-15.
Nasopharyngeal Cancer Professional Committee of the Chinese Anti-Cancer Association .
Chinese Journal of Radiation Oncology.
2018; 27(1): 7-15.

https://ascopubs.
org/doi/abs/10.
1200/JCO.
2020.
38.
15_suppl.
6521.

https://ascopubs.
org/doi/abs/10.
1200/JCO.
2020.
38.
15_suppl.
6521.


Leave a message here